Skip to content

Analysis of the changes of biliary and intestinal microecology after ERCP for primary choledocholithiasis and the correlation with recurrence

Analysis of the changes of biliary and intestinal microecology after ERCP for primary choledocholithiasis and the correlation with recurrence

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100045030
Enrollment
Unknown
Registered
2021-04-03
Start date
2021-04-01
Completion date
Unknown
Last updated
2021-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary bile duct stones

Interventions

Primary group:None

Sponsors

Guangdong Second Provincial General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.The diagnosis of primary choledocholithiasis was based on clinical manifestations and imaging evidence, including ultrasound, upper abdominal CT, MRI or MRCP, etc., and retrograde cholangiography was performed during ERCP to confirm the diagnosis; 2.ERCP examination, EST and choledocholithotomy were performed; 3.Aged 18-70 years; 4.Inform the patients and their family members of the content and purpose of this study, and inform them that blood, bile, feces and their auxiliary examination results may be used in this study, and sign the consent form.

Exclusion criteria

Exclusion criteria: 1.Patients with digestive tract malignant tumor, liver cirrhosis, pancreatitis, postoperative digestive tract reconstruction and biliary tract malformation; 2.Long term follow-up or missing clinical data were not available; 3.Pregnant and lactating women; 4.Patients with severe heart, lung and cerebrovascular diseases, liver and kidney dysfunction (ALT and AST are 2 times higher than the upper limit of the normal value in our laboratory; serum creatinine and urea nitrogen are 1.5 times higher than the upper limit of the normal value in our laboratory); 5.The vital signs were not stable; 6.Suspected or confirmed history of alcohol or drug abuse; 7.Participants in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Bile 16S rDNA;

Countries

China

Contacts

Public ContactTan Wenhui

Guangdong Second Provincial General Hospital

799350741@qq.com+86 13632432330

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026